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Vectors based on adeno-associated viruses (AAV) have shown considerable promise in
both preclinical models and increasingly in clinical trials. However, one formidable chal-
lenge is pre-existing immunity due to widespread exposure to numerous AAV variants and
serotypes within the human population, which affect efﬁcacy of clinical trials due to the
accompanying high levels of anti-capsid neutralizing antibodies.Transient immunosuppres-
sion has promise in mitigating cellular and humoral responses induced by vector application
in naïve hosts, but cannot overcome the problem that pre-existing neutralizing antibodies
pose toward the goal of safe and efﬁcient gene delivery. Shielding of AAV from antibod-
ies, however, may be possible by covalent attachment of polymers to the viral capsid
or by encapsulation of vectors inside biomaterials. In addition, there has been consider-
able progress in using rational mutagenesis, combinatorial libraries, and directed evolution
approaches to engineer capsid variants that are not recognized by anti-AAV antibodies gen-
erally present in the human population. While additional progress must be made, such
strategies, alone or in combination with immunosuppression to avoid de novo induction
of antibodies, have strong potential to signiﬁcantly enhance the clinical efﬁcacy of AAV
vectors.
Keywords: adeno-associated virus, viral vector, immune response, neutralizing antibodies, bioconjugation, muta-
genesis, directed evolution
INTRODUCTION
AAV BIOLOGY
Adeno-associated virus (AAV) is a non-pathogenic parvovirus
composed of a 4.7-kb single-strandedDNAgenome packaged into
a non-enveloped, icosahedral capsid (Knipe and Howley, 2006).
The viral genome contains three open reading frames (ORF)
between two inverted terminal repeats (ITR), which function as
the origin of replication and as the packaging signal (Knipe and
Howley, 2006). The rep ORF encodes four non-structural pro-
teins that function in viral replication, transcriptional regulation,
site-speciﬁc integration, and virion assembly (Knipe and Howley,
2006). The cap ORF encodes three structural proteins that assem-
ble to form a 60-mer viral capsid (Knipe and Howley, 2006). An
alternative ORF located in the same region of the genome pro-
duces the assembly activating protein (AAP; Sonntag et al., 2010),
a viral protein that localizes AAV capsid proteins to the nucleo-
lus and functions in the capsid assembly reaction (Sonntag et al.,
2010).
The capsid proteins determine the virus’ ability to interact
with and infect cells, from their initial binding to various cell
surface receptors, to their trafﬁcking inside the cell, to gaining
access to the nucleus. Speciﬁcally, AAV is internalized rapidly via
receptor-mediated endocytosis from clathrin-coated pits (Bartlett
et al., 2000). Following cellular internalization, the virion escapes
from early endosomes and trafﬁcs to the perinuclear area. Evi-
dence exists for AAV uncoating prior to viral DNA entry into
the nucleus (Lux et al., 2005), as well as viral trafﬁcking into the
nucleus prior to uncoating (Bartlett et al., 2000; Sonntag et al.,
2006). In either case, once AAV localizes to the nucleus, second-
strand synthesis – i.e., conversion of its single-stranded genome
into double-stranded, transcriptionally active DNA – must occur
for viral gene expression (Ferrari et al., 1996). In the absence of
helper virus co-infection, AAV enters a latent life-cycle with viral
genomes integrated in human chromosome 19 or non-integrated
as extrachromosomal episomes.
Recombinant versions of AAV can be created in which a gene
of interest is inserted between the ITRs, and the ORFs for struc-
tural and non-structural proteins are supplied separately (Flotte,
2004). This system allows the gene of interest to be packaged
inside the viral capsid and delivered to the cell. Dividing as well
as non-dividing cells are transduced, and gene expression – which
occurs in the absence of helper virus function – is stable for years
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in post-mitotic tissue. There are several naturally occurring vari-
ants and serotypes of AAV, each of which differs in amino acid
sequence, in particular in the hypervariable regions of the cap-
sid proteins, and thus in their gene delivery properties (Wu et al.,
2006; Schaffer et al., 2008). Importantly, no AAV has been associ-
ated with any human disease, making it a desirable gene delivery
vector for clinical applications (Knipe and Howley, 2006).
CLINICAL TRIALS INVOLVING AAV
Adeno-associated virus has been employed with promising results
in a number of clinical trials. During a Phase I dose-escalation
trial for gene therapy of Leber’s congenital amaurosis (LCA),
for example, all 12 patients who received a subretinal injection
of AAV2 encoding a protein required for the isomerohydrolase
activity of retinal pigment epithelium showed sustained improve-
ment in both subjective and objective measurements of vision
(Bainbridge et al., 2008; Maguire et al., 2008, 2009). Further-
more, there were no signiﬁcant adverse events during either the
pre-trial efﬁcacy studies or the Phase I trials (Bainbridge et al.,
2008; Maguire et al., 2008, 2009). As another example, in a
Phase I study for gene therapy of Canavan disease, 10 patients
received intracranial infusions of AAV2 encoding human aspar-
toacylase (McPhee et al., 2006). Of importance with respect to
vector re-application, 7 out of 10 patients in this trial had low
or undetectable levels of neutralizing antibodies to AAV2 fol-
lowing administration of the gene therapy vector (McPhee et al.,
2006).
In contrast to these clinical studies, which targeted immune
privileged sites, anti-AAV host responses most likely mediated by
cytotoxic T-cells limited the therapeutic efﬁcacy of rAAV vectors
following intrahepatic and intramuscular administration. Brieﬂy,
a Phase I/II dose-escalation study in which patients received a
hepatic artery infusion of AAV2 encoding human Factor IX ini-
tially achieved therapeutic levels of Factor IX expression. However,
the therapeutic levelswere only present for 2months (Manno et al.,
2006), and follow-up experiments concluded that T-cell-mediated
immunity to the AAV capsid antigens induced the destruction of
AAV2-transduced hepatocytes (Manno et al., 2006). Furthermore,
all subjects had a several log increase in neutralizing antibody titer
following vector administration (Manno et al., 2006). Similarly,
in a gene therapy study on lipoprotein lipase (LPL) deﬁciency,
all eight patients achieved decreased median triglyceride levels
and increased local LPL protein levels and activity 12weeks post-
administration of the AAV1 vector encoding LPLS447X (Stroes
et al., 2008). But, also in this trial, triglyceride levels returned to
baseline levels 18–31months post-administration (Stroes et al.,
2008).
IMMUNE RESPONSES TOWARD AAV
Viruses are, in general, recognized by the innate immune sys-
tem and induce the production of inﬂammatory cytokines,
chemokines, and/or interferons that foster adaptive immune
responses. The latter mainly comprises induction of antibod-
ies produced by B lymphocytes following presentation of viral
antigens by antigen-presenting cells, as well as direct cell killing
mediated by cytotoxic T-cells (Knipe and Howley, 2006).
Knowledge on the mechanisms that lead to recognition and
elimination of AAV in particular is still limited. Only recently, Zhu
et al. (2009) provided evidence thatAAV’s genome is recognized by
the innate immune system through theToll-like receptor 9-MyD88
pathway. In this study, plasmacytoid dendritic cells (pDCs) were
identiﬁed as sentinel cells, and activation of the Toll-like recep-
tor 9-MyD88 pathway was shown to elicit humoral and cytotoxic
T-lymphocyte immune responses in mice.
Humans become naturally infected by numerous AAV
serotypes, and in particular AAV2, during childhood, as indicated
by sero-conversion. As a result of this exposure, memory B and
eventually memory T-cells are induced. The latter are assumed to
be the cause for the lack of long-term gene expression and loss
of therapeutic efﬁcacy in the clinical trials on hemophilia and on
LPL mentioned above. Currently, it is not clear how this response
is launched, and consequently strategies for its avoidance are lack-
ing. One hypothesis is that memory T-cells were re-activated upon
vector administration through presentation of capsid fragments
following intracellular degradation of incoming capsids. Alterna-
tively, contamination of the gene therapy vector preparations with
cap DNA impurities could result in persistent expression of capsid
antigens and thus the destruction of transduced cells, though a
detailed analysis was unable to ﬁnd cap DNA sequences in the vec-
tor preparation used for the hemophilia trial (Hauck et al., 2008).
Should this prove to be a problem, microRNA approaches or an
oversized cap ORF could be employed to avoid de novo capsid
production and consequently MHC loading following AAV vector
application (Halbert et al., 2011; Lu et al., 2011). Employing these
strategies may help to reduce the cytotoxic immune response to
successfully transduced cells. Furthermore, immunosuppression
is exploited as a strategy to avoid induction of T as well as of B cell
responses (Jiang et al., 2006). An as of yet even greater challenge
is the high prevalence of pre-existing neutralizing antibodies that
signiﬁcantly hamper the efﬁcacy of de novo cell transduction.
Natural exposure to AAV serotypes 1, 2, 5, 6, 8, and 9 results
mainly in production of IgG1, but low amounts of IgG2, IgG3,
and IgG4 antibodies are also produced (Boutin et al., 2010). With
respect to the total anti-AAV IgG prevalence for each serotype,
a recent, comprehensive analysis revealed that AAV2 (72%) and
AAV1 (67%) antibodies were the most common, but AAV9 (47%),
AAV6 (46%), AAV5 (40%), and AAV8 (38%) antibodies were also
present in a large portion of the population studied (Boutin et al.,
2010). Furthermore, these anti-AAV antibodies may cross-react
with other related AAV serotypes. Differences in antibody preva-
lence in the human population are likely due to human genetic
variation and/or frequency of exposure to the various serotypes.
Animal studies on the mechanisms of anti-AAV antibody
induction using class I-deﬁcient (unable to mount a cellular
immune response) and class II-deﬁcient (unable to mount a
humoral response) mice found that the latter could readily express
high levels of transgenes upon a second administration of the
vector (Manning et al., 1998). In addition, using several types of
immunodeﬁcient mice (RAG1 knock-out, CD40 ligand knock-
out, and nude), Chirmule et al. (2000) showed that the AAV
neutralizing antibody response is T-cell dependent. Viral capsid
antigens are presented to B cells in the lymph nodes, resulting
in CD4+ T-cell activation (Bessis et al., 2004). The B cells then
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differentiate into plasma cells, which produce antibodies against
the viral capsid proteins (Bessis et al., 2004). The route of admin-
istration has been shown to also have an impact on the induction
of immune responses. Rhesus macaques receiving wild-type AAV
via intramuscular or intravenous injection developed a humoral
immune response to the AAV capsid, even without helper virus
co-infection, while animals that received vectors via the intranasal
route did not develop an immune response unless co-infectedwith
a helper virus (Hernandez et al., 1999). Analogous results on the
role of route of administration have been found in mice. Ge et al.
(2001) found that intramuscular vector administration was more
effective at inducing a humoral immune response than intraportal
vein delivery. Nevertheless, independent of the initial administra-
tion route, re-administration of AAV vectors via the tail vein did
not lead to transgene expression (Ge et al., 2001).
Recently, an AAV variant derived from rhesus macaques
(AAVrh32.33) was found to elicit an immune response in mice
similar to that against other AAV vectors seen in primate species
(Mays and Wilson, 2009). Speciﬁcally, this AAV generates a strong
CD8+T-cell response to theAAVcapsid and to the delivered trans-
gene in mice, and its use may thus provide a more accurate murine
model of AAV immune activation, and help to better explain the
loss of transgene expression in human gene therapy clinical trials.
In parallel to developing a deeper mechanistic understanding of
anti-vector immune responses, for AAV to effectively function in
clinical gene therapy, strategiesmust be developed to create vectors
that evade the body’s immune response.
STRATEGIES TO AVOID NEUTRALIZATION BY HUMORAL
ANTI-AAV IMMUNE RESPONSES
TRANSIENT IMMUNOSUPPRESSION
In the naïve host, humoral immune responses are elicited upon
AAV vector application. In order to circumvent induction of
this response, transient immunosuppression has been exploited.
This strategy has been tested in preclinical animal models, using
antibodies or small molecule inhibitors against T-cell function-
ality. Manning et al. (1998) reported that successful vector re-
administration was achieved in 60% of mice treated with anti-
CD40 antibodies during the ﬁrst vector administration. However,
the mice developed neutralizing antibodies to AAV following the
second administration of the vectors, which was conducted with-
out immunosuppression (Manning et al., 1998). Another study
by Halbert et al. (1998) attempted transient immunosuppres-
sion using MR1 (a monoclonal anti-CD40 ligand antibody) and
CTLA4Ig (a CTLA4-immunoglobulin fusion protein) alone or
in combination. Mice that received only MR1 or CTLA4Ig were
capable of expressing the delivered transgene, but at a lower level
than the combination treatment in which the animals also devel-
oped low to undetectable levels of neutralizing antibodies to AAV.
Also in these animals, neutralizing antibodies were elicited upon
re-administration (Halbert et al., 1998).
In response to the above mentioned clinical trial that reported
destruction of AAV2-FIX transduced hepatocytes (Manno et al.,
2006), Jiang et al. (2006) tested transient immunosuppression as a
means to preventAAV capsid-directed T-cell response against liver
cells expressing the FIX transgene. Immunosuppression of rhesus
macaques was achieved using a combination of mycophenolate
mofetil and tacrolimus (FK506). Neither transaminitis nor expan-
sion of memory T-cells was observed in any of the animals, and
consequently only the impact of immunosuppression on humoral,
but not on anti-capsid T-cell responses, could be investigated.
Of the three animals receiving immunosuppression during vec-
tor administration, one developed a strong anti-AAV antibody
response. Furthermore, withdrawal of the immunosuppression
therapy after 6 weeks lead to a 2-log increase in neutralizing anti-
body titer, revealing that at least in rhesus macaques long time
immunosuppression is required (Jiang et al., 2006).
In summary, immune suppression is an effective strategy to
mitigate the body’s immune response long enough to allow the
capsid proteins to clear from the cell surface and prevent the
formation of neutralizing antibodies in order to facilitate re-
administration of the vector. However, transient immunosuppres-
sion is not a solution to pre-existing neutralizing antibodies to
the AAV capsid. Modiﬁcations, either chemical modiﬁcations that
protect surface exposed parts of the protein capsid or geneticmod-
iﬁcations that result in changes to the protein capsid,must bemade
to the vector to evade these neutralizing antibodies.
CHEMICAL MODIFICATION OF AAV CAPSID TO AVOID ANTIBODY
NEUTRALIZATION
One approach to reduce antibody neutralization of vector par-
ticles is to graft chemical moieties onto the virion surface to
shield neutralizing epitopes, as recently reviewed (Jang et al.,
2011). For example, crosslinking synthetic polymers onto the vec-
tor can reduce neutralization by anti-virus antibodies as well as
enable evasion of innate immune responses, thereby enhancing
gene transfer in the presence of existing antibodies and facilitating
repeated administrationby reducing subsequent adaptive immune
responses to the vector (Kreppel and Kochanek, 2008). Polymeric
materials that have been explored in conjunction with adenoviral
and adeno-associated viral vectors have included polyethylene gly-
col (PEG; O’Riordan et al., 1999; Croyle et al., 2000, 2005; Cheng
et al., 2003; De Geest et al., 2005; Eto et al., 2005; Lee et al., 2005;
Mok et al., 2005; Oh et al., 2006; Hofherr et al., 2007), poly-N -(2-
hydroxypropyl) methacrylamide (poly-HPMA; Fisher et al., 2001;
Green et al., 2008), polysaccharides (Espenlaub et al., 2008), and
others (Kasman et al., 2009; Kim et al., 2010). They are typically
covalently conjugated through the reaction of active groups on
the polymer termini to nucleophilic amino acid side chains on the
viral surface, such as lysines and cysteines.
Polyethylene glycol is a non-toxic material known for its capac-
ity to resist protein binding – likely through steric hindrance and
blocking of protein surface charges – and it has been extensively
conjugated to proteins to extend their circulatory half-life and
reduce immune responses (Delgado et al., 1992; Edwards et al.,
2003; Haag and Kratz, 2006; Romberg et al., 2008). Likewise,
PEGylation has been utilized to protect viral vectors from neu-
tralizing antibodies (O’Riordan et al., 1999; Croyle et al., 2001;
Cheng et al., 2003; De Geest et al., 2005; Eto et al., 2005; Lee et al.,
2005; Mok et al., 2005; Hofherr et al., 2007), enable vector retar-
geting (Oh et al., 2006), and enhance vector stability (Croyle et al.,
2000). Several studies have PEGylated AAV, using several differ-
ent crosslinking chemistries. In one report, high molecular weight
PEG conjugated to AAV using a terminal N -hydroxysuccinimidyl
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ester to attach the polymer to viral surface lysines modestly pro-
tected AAV from neutralizing serum in culture (2.3-fold) at inter-
mediate levels of PEG/virus. However, above a key stoichiometric
ratio of PEG/AAV, viral infectivity was lost for both high and low
molecular weight PEG, presumably due to a loss of key lysine
residues and/or steric hindrance of viral surface regions critical
for viral infectivity. This loss of infectivity was accompanied by
alterations of AAV particles that could be visualized by electron
microscopy (i.e., virion shape and size; Lee et al., 2005). Another
study, which used different PEGylation chemistries, found more
positive results. Speciﬁcally, AAV reacted with PEG using suc-
cinimidyl succinate chemistry (SSPEG) was partially protected
from antibodies. In contrast, AAV coated with PEG via tresyl
chloride reactive groups (TMPEG) was more effectively protected
from neutralizing antibodies both in vitro and in vivo (Le et al.,
2005). Over time, hydrolysis of the SSPEG linkages may progres-
sively unmask antigen binding sites, rendering this conjugation
less effective.
Other human viruses also face challenges with pre-existing
immunity, and chemical conjugation has, for example, been more
extensively explored to shield adenoviral vectors from serum,
including both PEG (Croyle et al., 2005; De Geest et al., 2005;
Mok et al., 2005; Kasman et al., 2009) and other polymers such as
poly-HPMA (Fisher et al., 2001; Green et al., 2008). In one study,
adenoviral vectors were coated with a random copolymer contain-
ing N -(2-hydroxypropyl)methacrylamide and methacryloyl-Gly-
Gly-4-nitrophenoxy (pHPMA–ONp),via reactionwith adenoviral
surface amino groups. A binding assay involving ELISA measure-
ment of free antibodies found that even at high excess, coated
virus did not deplete anti-viral antibodies from solution, indi-
cating the polymer shielded the adenovirus from the antibodies.
Furthermore, since polymer coatings can block regions responsi-
ble for natural viral tropism, this modiﬁcation afforded the further
opportunity to retarget the virus via addition of ﬁbroblast growth
factor (FGF)-2 or vascular endothelial growth factor (VEGF) to the
polymer. Adenoviral vectors coated with the polymer plus FGF-
2 were 10-fold more resistant to antibody neutralization in vitro
(Fisher et al., 2001). In addition, the vectors exhibited selective
delivery to cell lines expressing receptors for FGF-2 or VEGF,
depending on the ligand attached to the particle surface.
In addition to direct polymer grafting, an alternate strategy
for protecting vectors from serum is to encapsulate them inside
polymeric gels or particles designed to progressively degrade and
release the virus (Jang et al., 2011). In early work, Beer et al. (1998)
encapsulated adenovirus in poly-lactic glycolic acid using a dou-
ble emulsion technique. They found that the encapsulated virus
retained 27–50 and 62–65% infectivity in culture at 1:100 and
1:500 dilutions of rat serum, respectively, while non-modiﬁed
vectors retained less than 1% of infectivity at both dilutions. In
addition, they assessed the development of neutralizing antibod-
ies in naïve mice upon administration of protected vector and
found that animals receiving encapsulated adenovirus did not
develop anti-adenovirus antibodies until after the third dose, and
the resulting titers were 45-fold lower than mice receiving unmod-
iﬁed adenovirus (Beer et al., 1998). In another report, adenovirus
was encapsulated in microspheres generated from alginate, a lin-
ear copolymer of anionic saccharides isolated from brown algae.
Upon intranasal or intraperitoneal administration of virus-loaded
microspheres, high level LacZ expression was observed in numer-
ous organs inmice (including spleen, liver, lung,kidney,and lymph
node) and was not signiﬁcantly inhibited by the presence of neu-
tralizing anti-adenovirus antibodies. By contrast, administration
of un-encapsulated control vector was signiﬁcantly reduced in
animals harboring neutralizing antibodies (Sailaja et al., 2002).
In summary, direct chemical conjugation of protective poly-
mers toAAV shows promise, thoughwith somewhatmixed results,
and future work may investigate the application of alternate poly-
mers and controlled release strategies that have shown promise
with adenoviral and other vectors.
GENETIC MODIFICATION OF AAV CAPSID PROTEINS TO AVOID
ANTIBODY NEUTRALIZATION
As suggested by the term “serotype,” AAV variants with unique
serological characteristics have evolved in nature (Gao et al., 2004).
Variations in the amino acid composition of the capsid proteins,
in particular at protruding sites, can lead to low serum cross-
reactivity between serotypes (Lochrie et al., 2006). For example,
mice immunized with AAV2 show only a slight reduction in
transduction efﬁcacy if subsequently injected with AAV1 (which
differs from AAV2 at 16.3% of the capsid amino acids; Gao
et al., 2004), while anti-AAV2 antibodies impair re-application
of AAV2 (Xiao et al., 1999). In principle, such ﬁndings raise the
idea that one could harness natural AAV diversity to overcome
problems of pre-existing immunity. That is, identiﬁcation of one
or more serotypes to which speciﬁc patients have not previously
been exposed could allow recombinant vector administration or
even re-administration. This idea suffers from several problems,
however. First, such personalized therapy poses practical and reg-
ulatory concerns. In addition, capsid variability among serotypes
affects not only antigenicity but also tropism, so that different
serotypes could not be readily alternated. Furthermore, the pat-
terns of pre-existingAAV immunity within the human population
are complex (Boutin et al., 2010). As already mentioned, sera are
frequently found to neutralize more than one serotype, and for
example in>93% of sera positive for AAV2, neutralizing antibod-
ies toward AAV1 are additionally present. Interestingly, antibodies
against these two serotypes were also detectable in sera positive for
AAV5, 6, 8, or 9 (Boutin et al., 2010). However, the observation
that different serotypes exhibit different extents of cross-reactivity
raises the idea that a given capsid can be engineered or mutated
to retain the natural tropism of, yet evade pre-existing antibod-
ies directed against, its parental serotype. Both rational design and
directed evolution approaches have been pursued toward this goal.
Peptide scanning for immunogenic epitopes
The rational design of AAV variants that evade pre-existing
humoral immunity necessitates basic knowledge of immunogenic
epitopes. In an early study, Moskalenko et al. (2000) utilized pep-
tide scanning to map neutralizing epitopes for antibodies present
in human serum samples and found a total of six linear epitopes
that are targets of neutralizing antibodies (Table 1). Wobus et al.
(2000) mapped additional linear and conformational immuno-
genic epitopes neutralized by mouse monoclonal antibodies. Lin-
ear epitopes in the VP1 unique region, in VP1/VP2, and at the
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Table 1 | Immunogenic sites of the AAV2 capsid mapped by peptide scan.
Amino acid position Localization Sera Reference
E17GIRQWWKLKPG VP1 Polyclonal human Moskalenko et al. (2000)
K123RVLEPLGL VP1 A1 Wobus et al. (2000)
N113LGRAVFQAKKR VP1 Polyclonal human Moskalenko et al. (2000)
L171NFGQTGDADSV VP1/VP2 A69 Wobus et al. (2000)
K321EVT## VP3 region Polyclonal human Moskalenko et al. (2000)
T337STV VP3 region Polyclonal human Moskalenko et al. (2000)
V369FMVPQYGYL (main contribution), H381YFGYSTPWG (minor
contribution), R566TTNPVAT573EQ (minor contribution)
VP3 region A20 Wobus et al. (2000)
Q473SRNWLPGPCYR VP3 region Polyclonal human Moskalenko et al. (2000)
S474RNWLPGPCY# VP3 region D3 Wobus et al. (2000)
S493ADNNNSEYSWT (main contribution), L601PGMVWQDRD
(minor contribution)
VP3 region C37-B Wobus et al. (2000)
I726GTRYLTR VP3 region, C′-terminus B1 Wobus et al. (2000)
#Additional sequences likely contribute to the immunogenic epitope (Wobus et al., 2000).
##Described as part of a conformational epitope (Moskalenko et al., 2000).
C′-terminus of the VP3 region are recognized by antibodies A1,
A69, and B1, respectively (Table 1), while conformational epitopes
were bound by C24-B, C37-B, D3, and A20 (Table 2). In order
to map the latter, Wobus and colleagues used peptide insertion
mutants of AAV2 (Girod et al., 1999) that displayed an integrin
binding ligand, L14, at deﬁned and surface exposed positions of
the capsid (Wobus et al., 2000).
The same mutants were subsequently screened for their
immune escape phenotype by Huttner et al. (2003) using a panel
of humanpolyclonal sera. Forty-twopercentage of the sera showed
a signiﬁcant reduction (∼31%) in antibody binding afﬁnity when
the capsid position 534 or 573 were subjected to peptide inser-
tion, while 21% of the sera additionally showed a reduced binding
afﬁnity for the other sixmutants (Table 2). These ﬁndings for poly-
clonal human sera agreed with the results of Wobus et al. (2000)
obtained with mouse monoclonal antibodies and identiﬁed posi-
tions 534 and 573 as major antigenic determinants in humans.
Peptide insertion not only impacts antibody binding afﬁnity, but
also the transduction ability. Further investigations by Huttner
et al. (2003) revealed that the peptide insertion mutant I-587,
which displayed the L14 peptide at position 587 as ligand for tar-
geting B16F10 cells, transduced this cell line despite the presence
of neutralizing antibodies. Exchanging the peptide for a 7-mer
peptide targeting Mec1 cells (Perabo et al., 2003) yielded similar
results, demonstrating that insertion of peptides at 587 can modu-
late both cell tropism and antibody neutralization (Huttner et al.,
2003).
Rational design of AAV variants via peptide insertion or
site-directed mutagenesis
Lochrie et al. (2006) utilized extensive site-directed mutagenesis
of the AAV2 capsid to develop variants with immune escaping
properties. In silico structural analysis of potential docking for a
murine IgG2a antibody with the AAV2 surface yielded a number
of sterically accessible, candidate positions that were then sub-
jected to point mutagenesis. The resulting collection of mutants
were assessed for antibody binding using A20 (mouse anti-AAV2
capsid antibody), human sera (three different donors), and IVIG
(pooled human IgG isolated from thousands of blood donors). As
may be anticipated for polyclonal antibody mixtures, in contrast
to work with A20 that identiﬁed a set of variants with mutations
at a speciﬁc epitope, analysis with human sera (single donors)
and IVIG did not map a single epitope. At any rate, point muta-
tions at distinct sites spread across the capsid reduced immune
neutralization.
Directed evolution of AAV variants via random mutagenesis
In contrast to rational design based approaches, directed evolu-
tion strategies can be exploited in the absence of knowledge on the
capsid biology or on immunogenic sites. This strategy is based on
the generation and high-throughput selection of diverse genetic
libraries to create variants with enhanced biological functions
(Neylon, 2004). Maheshri et al. (2006) and Perabo et al. (2006)
applied this technology to AAV to overcome the obstacle of pre-
existing immunity. Both approaches used error-prone mutagene-
sis to randomize theAAV2 capsid. Random point mutations to the
AAV cap ORF are introduced using a “sloppy” polymerase chain
reaction (PCR) to amplify and mutate the cap DNA sequence at a
deﬁned rate. The PCR conditions can be adjusted to tune the aver-
age number of mutations in each cap gene sequence (Figure 1A;
Pritchard et al., 2005). Viral capsid mutants are then packaged by
standard production protocols and screened for infectivity despite
the presence of neutralizing antibodies. Progeny production is
induced by helper virus co-infection and followed by a new round
of selection.
Perabo et al. (2006) selected in presence of human sera on a
highly permissive cell line, HeLa. In contrast to selections in the
presence of non-neutralizing sera, selections in the presence of
neutralizing antibodies yielded viral mutants in which 73% of
point mutations clustered in the same, surface exposed region.
The most frequent selected clones carried mutations at capsid
positions 459 and 551. Introduction of selected amino acid substi-
tution at position 459 and/or 551 of capsids of recombinant AAV
vectors conferred the vectors with an improved ability to evade
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Table 2 | Immunogenic sites at the AAV2 capsid#.
Amino acid
position
Localization Sera Detection method Reference
E12 VP1 unique region Polyclonal rabbit In vitro evolution Maheshri et al. (2006)
S42 VP1 unique region Polyclonal rabbit In vitro evolution Maheshri et al. (2006)
A117 VP1 unique region Polyclonal rabbit In vitro evolution Maheshri et al. (2006)
A152 VP1/VP2 Polyclonal rabbit In vitro evolution Maheshri et al. (2006)
D180 VP1/VP2 Polyclonal rabbit In vitro evolution Maheshri et al. (2006)
K258 VP3 region Polyclonal rabbit In vitro evolution Maheshri et al. (2006)
S261-S262 VP3 region A20, C37-B, D3 (*),
polyclonal human
Peptide insertion Wobus et al. (2000),
Huttner et al. (2003)
Q263 VP3 region, edge of plateau A20 Rational design Lochrie et al. (2006)
S264 VP3 region, edge of plateau A20, IVIG Rational design Lochrie et al. (2006)
G265 VP3 region IVIG Rational design Lochrie et al. (2006)
D269 VP3 region IVIG Rational design Lochrie et al. (2006)
N381-N382 VP3 region A20, D3 (*), polyclonal
human
Peptide insertion Wobus et al. (2000),
Huttner et al. (2003)
S384 VP3 region, edge of plateau A20 Rational design Lochrie et al. (2006)
Q385 VP3 region, edge of plateau A20 Rational design Lochrie et al. (2006)
V418 VP3 region Polyclonal rabbit In vitro evolution Maheshri et al. (2006)
R447-T448 VP3 region C37-B, polyclonal human Peptide insertion Huttner et al. (2003)
R459 VP3 region, threefold
symmetry axis
polyclonal human In vitro evolution Perabo et al. (2006)
R471 VP3 region Polyclonal human, IVIG Rational design Lochrie et al. (2006)
T491 VP3 region IVIG Rational design Lochrie et al. (2006)
A493 VP3 region Polyclonal rabbit In vitro evolution Maheshri et al. (2006)
N497 VP3 region Polyclonal human, IVIG Rational design Lochrie et al. (2006)
S498 VP3 region Polyclonal human, IVIG Rational design Lochrie et al. (2006)
W502 VP3 region IVIG Rational design Lochrie et al. (2006)
K527 VP3 region IVIG Rational design Lochrie et al. (2006)
E531 VP3 region Polyclonal human, IVIG Rational design Lochrie et al. (2006)
K532 VP3 region IVIG Rational design Lochrie et al. (2006)
F534-F535 VP3 region A20, C24-B, C37-B, D3 (*),
polycloncal human
Peptide insertion Wobus et al. (2000),
Huttner et al. (2003)
K544 VP3 region IVIG Rational design Lochrie et al. (2006)
E548 VP3 region, spike region A20, polyclonal human Rational design Lochrie et al. (2006)
T550 VP3 region Polyclonal human, IVIG Rational design Lochrie et al. (2006)
N551 VP3 region, threefold
symmetry axis
Polyclonal human In vitro evolution Perabo et al. (2006)
T567 VP3 region Polyclonal rabbit In vitro evolution Maheshri et al. (2006)
T573-E574 VP3 region A20, C24-B, C37-B, D3 (*),
polyclonal human
Peptide insertion Wobus et al. (2000),
Huttner et al. (2003)
E574 VP3 region IVIG Rational design Lochrie et al. (2006)
G586 VP3 region Polyclonal human, IVIG Rational design Lochrie et al. (2006)
N587 VP3 region, threefold
symmetry axis, heparin
binding motif
Polycloncal rabbit, polyclonal
human
In vitro insertion,
rational design
Maheshri et al. (2006),
Lochrie et al. (2006)
N587-R588 VP3 region C24-B, C37-B, polyclonal
human
Peptide insertion Wobus et al. (2000),
Huttner et al. (2003)
N705 VP3 region Polyclonal human, IVIG Rational design Lochrie et al. (2006)
K706 VP3 region Polyclonal human Rational design Lochrie et al. (2006)
V708 VP3 region, edge of plateau A20, polyclonal human, IVIG Rational design Lochrie et al. (2006)
(Continued)
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Table 2 | Continued
Amino acid
position
Localization Sera Detection method Reference
T713 VP3 region Polyclonal rabbit In vitro evolution Maheshri et al. (2006)
T716 VP3 region, surface of the
twofold dimple
Polyclonal rabbit In vitro evolution Maheshri et al. (2006)
#Viral vectors, i.e., intact capsid assayed.
(∗)Reduced binding afﬁnity maybe due to a conformational change in the epitope caused by the peptide insertion (Wobus et al., 2000).
A20=mouse monoclonal antibody (Wistuba et al., 1995), conformational epitope.
C37-B=mouse monoclonal antibody (Wobus et al., 2000), conformational epitope.
Human sera= serum obtained from single donors.
IVIG=puriﬁed human IgG prepared from thousands of blood donors.
FIGURE 1 | Schematic of library AAV capsid protein engineering
strategies for evasion of antibody neutralization. Methods for generation
of highly diverse viral libraries include (A) random point mutagenesis
(error-prone PCR) and (B) in vitro recombination (DNA shufﬂing). Directed
evolution strategies use these approaches as part of an iterative strategy to
increase AAV’s ability to avoid antibody neutralization.
neutralization. The highest immune evasion was observed for the
sera used to select the mutants, but with each of the seven different
sera assayed, a notable higher serum concentrationwas required to
halve the transduction efﬁcacy of the mutants compared to AAV2
(up to 5.3-fold).
The viral library used by Perabo et al. (2006) possess on
average 0.9 mutations per clone making it unlikely that mul-
tiple combinations of mutations are found on a single clone.
The latter, however, increases the likelihood of selecting potent
immune escaping variants. An efﬁcient strategy to achieve this
goal was exploited by Maheshri et al. (2006), who combined error-
prone PCR mutagenesis and DNA shufﬂing, in their approach
to establish directed evolution strategies for AAV. Random DNA
recombination (Figure 1B) can be achieved using several different
methods, including the staggered extension process (StEP) recom-
bination (Zhao et al., 1998; used by Maheshri et al., 2006) and
DNase I digestion followed by fragment reassembly with DNA
polymerase (Stemmer, 1994; used by Grimm et al., 2008; Koerber
et al., 2008). The StEP consists of repeated cycles of denatura-
tion, annealing, and short polymerase-catalyzed extension steps.
The abbreviated extension step results in short fragments of DNA
that can then anneal to new templates and further extend, creating
genes that contain sequence information from multiple templates.
DNA shufﬂing uses DNase I digestion to create small fragments
of DNA similar to the fragments created in StEP. These fragments
are then reassembled into new genes through repeated annealing
cycles in the presence of DNA polymerase. Both methods can be
used to create point mutations (when all cap gene templates are
from the same serotype) or to generate chimeric capsids (when
cap gene templates are from different serotypes).
The viral library produced by Maheshri et al. (2006) was
selected for mutants that productively infect HEK293 in the pres-
ence of a strongly neutralizing rabbit anti-AAV2 serum. Interest-
ingly, each mutant selected in this screen contained a threonine to
alanine substitution at position 716, near the C-terminus of the
common VP3 region. In order to further optimize the selection
procedure, the viral library was subjected to a further round of
mutagenesis. While transduction of AAV2 in the presence of rab-
bit sera was neutralized at a 1:1,500 dilution, the most promising
candidate of the second screen was only mildly neutralized at a
www.frontiersin.org October 2011 | Volume 2 | Article 204 | 7
Bartel et al. AAV capsid engineering to evade immunity
1:2.35 serum dilution. More importantly, this mutant mediated
transgene expression in vivo following pre-incubation with anti-
AAV serum at levels 2–3 orders of magnitude higher than serum
concentrations that neutralized AAV2 (Maheshri et al., 2006).
To date, AAV libraries based on error-prone PCR mutagenesis
possess a diversity of 107–108 clones (Maersch et al., 2009). How-
ever, in order to screen every possible amino acid substitution for
their immune escape properties, a diversity of 3.2× 1017 would
be required (Maersch et al., 2009). A possibility to overcome this
technical limitation and identify the most effective amino acid
substitution for a given position, and hence improve the anti-
body evasion capacity of immune escape mutants was proposed
by Maersch et al. (2009). In this procedure, only regions impli-
cated as immunogenic sites are randomized, and these mutants
are subjected to high-throughput selections for viral infectivity in
the presence of neutralizing sera. In their proof-of-principle study,
Märsch and colleagues focused on ﬁve immunogenic sites: posi-
tions 449, 558, 459, 551, and 493 (Maheshri et al., 2006; Perabo
et al., 2006; Maersch et al., 2009), which were subjected to satura-
tion mutagenesis. Due to this restriction, the library purportedly
contained all possible amino acid substitutions for these posi-
tions (required diversity 205, obtained diversity 6× 106). From
the mutants selected in the presence of human sera on HEK293
cells, six mutants were analyzed in comparison to AAV1, AAV2,
and AAV2 R459K/N551D, a double mutant selected in the pre-
vious study of Perabo et al. (2006). Two of these mutants were
signiﬁcantly less neutralized by human sera from single donors
and by IVIG compared to AAV2 and AAV2 R459K/N551D. In
agreement with the initial hypothesis that the level of immune
evasion can be improved if an optimal amino acid substitution
is introduced to disrupt an immunogenic epitope, both mutants
contained novel substitutions at positions 459, 493, and 551. In
addition, the relatively minor sequence changes – compared for
example to the 120 amino acid differences between AAV2 and
AAV1 – likely did not change the mutant’s tropism relative to
AAV2.
Directed evolution of AAV variants via serotype shufﬂing
Grimm et al. (2008) implemented an in vitro evolution strat-
egy that utilized a library of chimeric capsids. DNA shufﬂing
through fragment reassembly was exploited to randomly com-
bine cap sequences of eight AAV serotypes [AAV2, 4, 5, 8, and 9,
and caprine (CAAV), avain (AAAV), and bovine AAV (BAAV)].
The library was ﬁrstly selected for the ability to transduce human
hepatoma cell lines, followed by further selection in the presence
of IVIG. The result was a single mutant, AAV-DJ, a chimera of
AAV2, 8, and 9 in which the majority of non-AAV2 amino acid
sequences were found in immunogenic epitopes of the capsid.
For in depth analysis of the immune proﬁle of AAV-DJ, Grimm
et al. (2008) passively immunized mice with IVIG followed by vec-
tor injection. At lower IVIG levels, AAV-DJ possessed an in vivo
immune evasion capacity comparable to AAV8 and AAV9 as indi-
cated by the comparable level of transgene expression, though
both serotypes clearly outperformed AAV-DJ at a higher IVIG
concentration. Interestingly, although re-administration of AAV-
DJ was impaired, and although mice pre-immunized with AAV8
or 9 could not be transduced by AAV-DJ, AAV2, 8, and 9 were
able to mediate transgene expression in AAV-DJ pre-immunized
mice.
In another study involvingDNA shufﬂing of AAV,Koerber et al.
(2008) performed a detailed analysis of seven chimeric AAV vec-
tors, which had been selected in the absence of antibodies in a
single selection round for viability. The library used for their selec-
tion contained DNA shufﬂing based virus chimeras of AAV1, 2, 4,
5, 6, 8, and 9, i.e., they included additional non-human primate
serotypes but not more distantly related serotypes. Sequencing
of candidate chimeras revealed a greater than 90% similarity to
AAV2 for three of the mutants, and to AAV1 and 6 for the other
four mutants. In addition, all clones contained a high propor-
tion of sequences originating from non-AAV2 and non-AAV1/6
serotypes, respectively, in the surface exposed regions of the cap-
sid. Of note, four of these seven mutants showed, in the absence of
a selection pressure, a naturally greater resistance to neutralization
by IVIG than the parental serotypes. The highest immune evasion
capability was detected for a mutant with a greater than 90% simi-
larity to AAV1/6. This mutant, cB4, was 400-fold more resistant to
neutralization by IVIG than AAV2 and is as of yet one of the most
potent immune escaping AAV vectors. This work by Koerber et al.
(2008) and Grimm et al. (2008) clearly reveal the great potential
of chimeric virions. The immune evasion phenotype is, however,
due to a new combination of cap sequences of different serotypes
and thus requires the selection of chimeric mutants which in addi-
tion to immune evasion possess a desired tropism in order to fully
exploit this strategy to improve AAV’s in vivo application.
CONCLUSION
Adeno-associated virus possesses several characteristics that have
contributed to its growing popularity as a gene delivery vector
for clinical gene therapy applications. Unfortunately, pre-existing
neutralizing antibodies against the AAV capsid and humoral
immune responses following vector administration have pre-
ventedAAV fromreaching its full potential as a gene therapy vector.
Chemical modiﬁcations that protect exposed immunogenic epi-
topes of the capsid and genetic modiﬁcations that mutate these
epitopes have demonstrated that AAV vectors can be altered to
decrease antibody neutralization, while still effectively delivering
genetic material, both in vitro and in vivo. The modiﬁcation meth-
ods described above can be used to isolate new AAV variants with
more improved immune evasion characteristics and thus possibly
stronger clinical potential.
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